MetricSide LogoMetricSide
Learn
  1. Home
  2. Companies
  3. Healthcare
  4. OWLT
OverviewMetricsPricesRevenue & ProfitAssets & LiabilitiesCash FlowMarginsPrice RatiosOthers
MetricSide

Standardized stock fundamentals and valuation metrics. Analyze revenue, EBITDA, free cash flow, and more with interactive charts.

Stock Sectors

  • Technology
  • Healthcare
  • Financials
  • Consumer
  • Industrials
  • Energy
  • Real Estate
  • Materials

Legal & Contact

  • Terms of Service
  • Privacy Policy
  • Contact Us
Not Financial Advice: MetricSide is a data aggregation and visualization tool. Nothing on this website constitutes investment advice, a recommendation, or a solicitation to buy or sell any security. All data is provided for informational and educational purposes only. Past performance is not indicative of future results. Always consult a qualified financial professional before making investment decisions. Data accuracy is not guaranteed — verify critical information against official sources.

© 2026 MetricSide. All rights reserved.

Owlet (OWLT) Stock Fundamentals, Analysis & Risk Signals

Health score, price, valuation, risk signals, and key metrics at a glance.

Owlet
NYSE•Healthcare•Medical Devices
$4.98-0.05(-0.01%)Market closed
Market Cap
$129.46M
P/S
1.1x
P/B
5.6x

Owlet, Inc. provides digital parenting solutions in the United States, the United Kingdom, and internationally. The company offers a digital parenting platform that provides real-time data and insights to parents. It also provides sock monitors, including Dream Sock, a wearable infant health monitor equipped with pulse oximetry technology that tracks vital signs, such as pulse rate, activity, oxygen level, and sleep patterns; BabySat, which is intended for infants with conditions, including respiratory syncytial virus, pneumonia, bronchitis, croup, and other diagnoses; and Dream Sight, an audio and video monitor that enables parents to monitor their child. In addition, the company offers Dream Duo, which integrates Dream Sock and Dream Sight to create a connected health and safety system; Owlet360, a subscription service that provides personalized understanding of the babies' development, health, and sleep trends; and accessories, such as fabric accessory socks and the Owlet Sock Travel Case. The company was founded in 2012 and is headquartered in Lehi, Utah.

B

How this company scores

GoodMetricSide Score: 65/100

Strongest: Balance Sheet & Red Flags (23/25); weakest: Cash & Earnings Quality (5/25).

Profitability17/25
Growth20/25
Balance Sheet & Red Flags23/25
Cash & Earnings Quality5/25
Strengths
Growing revenueLong cash runwayLow leverageInterest easily covered

Valuation vs. 5-year range

Today's multiple positioned against its own trailing range — a visual premium/discount check.

P/S · 1.1x5y range 0.9x – 20.1x
P/S 1.1x · below its 20-quarter median

Currently below its 20-quarter median.

P/B · 5.6x5y range 5.6x – 165.4x
P/B 5.6x · below its 8-quarter median

Currently below its 8-quarter median.

Watch items

Data-driven signals worth keeping an eye on across the last 8 quarters

High Risk

Margin Pressure

Red Flag

The company posted negative operating margins in recent quarters — core operations are unprofitable.

Earnings Quality

Red Flag

Free cash flow has been negative in 7 of the last 8 quarters — earnings are not translating to cash.

Price & Volume
Market Cap $129.46M

Metrics at a Glance

as of June 2026

Revenue & Profit

Revenue, EBITDA, operating income, net income, EPS, and shares

TTM Revenue
$114.86M
6Q
Q. Revenue
$33.87M
30%
TTM EBITDA
$-6.73M
59%
TTM Op. Income
$-7.42M
56%
Q. Op. Income
$1.74M
191%
TTM Net Income
$-9.01M
82%
Q. Net Income
$-620,000
2Q
EPS
$-0.05
2Q
Shares Out.
$28.51M
6Q
$114.86M in TTM revenue grew 27.9% YoY, reaching $33.87M last quarter. TTM EBITDA of $-6.73M and TTM operating income of $-7.42M show growth is flowing through to the bottom line. However, net income is negative at $9.01M — growth is not yet reaching the bottom line. Across the last 8 quarters, TTM revenue has risen for 6 consecutive quarters — an improving trend.

Margins

Gross, EBITDA, operating, and net margin trends

Gross Margin
64.4%
2Q
EBITDA Margin
5.8%
183%
Op. Margin
5.1%
170%
Net Margin
-1.8%
2Q
Op. margin of 5.1% is up 12.5% YoY — cost efficiency is improving. Net margin at -1.8% and gross margin of 64.4% show how much of each revenue dollar survives to profit. Over the past year, operating margin is up 170% — an improving trend.

Price Ratios

P/E, P/S, P/B, EV/EBITDA, FCF yield, and earnings yield

P/E Ratio
N/A
P/S Ratio
1.1x
2Q
P/B Ratio
5.6x
2Q
P/S of 1.1x and P/B of 5.6x. P/S is low relative to typical market levels.

Assets & Liabilities

Total assets, cash, debt, book value, and leverage

Total Assets
$93.57M
6Q
Cash
$30.95M
2Q
Long-Term Debt
$0
7Q
Book Value
$23.14M
4Q
D/E Ratio
0.0
2Q
Debt/EBITDA
0.0
With $93.57M in assets and $0 in long-term debt, D/E is 0.0and book value is $23.14M — a conservative capital structure with a cushion to weather downturns. Across the last 3 quarters, debt/equity has fallen for 2 consecutive quarters — an improving trend.

Cash Flow

Operating cash flow, free cash flow, FCF margin, and earnings quality

Op. Cash Flow
$-92,000
96%
TTM Free Cash Flow
$-8.53M
2Q
FCF Margin
-7.4%
2Q
FCF / Net Income
0.9
264%
TTM FCF of $-8.53M on $-92,000 in operating cash flow. The FCF / Net Income ratio of 0.9x means free cash flow covers net income — earnings are backed by cash. Across the last 8 quarters, free cash flow has risen for 2 consecutive quarters — an improving trend.

Related Stocks in Healthcare

View Sector
LLY$938.28B
Lilly (Eli)
Drug Manufacturers - General
JNJ$586.47B
Johnson & Johnson
Drug Manufacturers - General
ABBV$411.57B
AbbVie
Drug Manufacturers - General
MRK$303.29B
Merck & Co.
Drug Manufacturers - General
UNH$249.74B
UnitedHealth Group
Healthcare Plans
TMO$203.77B
Thermo Fisher Scientific
Diagnostics & Research
AMGN$201.34B
Amgen
Drug Manufacturers - General
GILD$191.61B
Gilead Sciences
Drug Manufacturers - General

Cash Burn

Red Flag

The last 6 consecutive quarters had negative FCF — the company is burning cash and may need external funding.

Share Dilution

Red Flag

Shares outstanding increased 72.1% — significant dilution, likely from stock compensation or capital raises.